March 2026 in “Journal of Cancer Survivorship” Exercise may help reduce treatment side effects and improve survival in metastatic colorectal cancer.
February 2026 in “Oncology Reviews” Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.
January 2026 in “International Journal of Unani and Integrative Medicine” Combining modern and Unani medicine may better manage PCOS symptoms.
December 2025 in “International Journal of Medicine and Public Health” Overt hyperthyroidism is the most common thyroid disorder, especially in women.
November 2025 in “Journal of Disease and Public Health” Post-COVID-19 syndrome is complex, affects 5%-10% of people, and requires better research and global collaboration for treatment.
New-onset fibromyalgia after COVID-19 is poorly understood, needing better definitions and studies.
October 2025 in “Cermin Dunia Kedokteran” Chronic obstructive pulmonary disease (COPD) is managed with personalized medication to ease symptoms and improve life quality.
July 2025 in “Jurnal Farmasi Sains dan Praktis” Most adverse reactions to the treatment were mild, with nausea being the most common.
July 2025 in “International Journal of Pharmacology and Clinical Research” More public health efforts are needed to raise awareness and improve management of thyroid disorders.
January 2025 in “Open Life Sciences” Overexpression of the HE4 gene in mice causes eye inflammation and cloudiness.
Careful diagnosis and management of MCTD are crucial due to potential severe complications.
May 2024 in “Journal of clinical case studies reviews & reports” A man's health improved after treating his undiagnosed adrenal insufficiency, which caused fatigue and weight loss.
April 2024 in “Cell death and disease” Long COVID causes various long-term health issues and needs better awareness and treatment.
March 2024 in “Intisari Sains Medis” Low free thyroxine (FT4) is common in young lupus patients and needs quick diagnosis and treatment.
March 2024 in “World Journal Of Advanced Research and Reviews” Educators who survived COVID-19 faced physical, psychological, and social challenges but overcame them with resilience and support, highlighting the need for schools to provide better health and psychological care.
February 2024 in “Journal of ayurveda and integrated medical sciences” Ayurvedic medicine helped increase a young woman's hemoglobin levels and improved her anemia symptoms.
February 2024 in “Curēus” Long COVID is more common in those with severe initial infections, but not linked to blood group.
January 2024 in “International Research Journal of Modernization in Engineering Technology and Science” Fasting may reduce chemotherapy side effects.
January 2024 in “International Journal of Medicine in Developing Countries” Most people in Alahsa, Saudi Arabia, have low awareness of thyroid disease symptoms and risk factors.
December 2023 in “Tuberkuloz ve Toraks/Tüberküloz ve toraks” Many COVID-19 patients have long-term symptoms, especially women, but certain medications may help reduce these symptoms.
November 2023 in “Open Repository of the University of Porto (University of Porto)” Pharmacists play a crucial role in patient care and education.
October 2023 in “Dermatology practical & conceptual” Many patients experienced hair loss after COVID-19, with women affected more, starting on average 49 days post-infection.
October 2023 in “Dermatology practical & conceptual” Pulse corticosteroids help regrow hair in alopecia areata but have side effects, especially betamethasone.
Recognizing unusual brain and skin symptoms is crucial for diagnosing lupus early.
September 2023 in “medRxiv (Cold Spring Harbor Laboratory)” Long-COVID has diverse, long-term health impacts, especially in young people.
September 2023 in “Deleted Journal” Post-bariatric surgery patients often face gastrointestinal issues, fatigue, dry skin, hair loss, and anxiety.
January 2023 in “Open veterinary journal” A cat developed skin problems from a certain brand of injected water pills, which went away after switching brands.
There is no cure for myotonic dystrophy type 1, so treatment focuses on managing symptoms and complications.
Icosapent ethyl may help treat long-lasting symptoms after COVID-19.